Prophylactic clarithromycin to treat Mycobacterium avium in HIV patients receiving zidovudine may significantly increase mortality by suppressing lymphopoiesis and hematopoiesis

International Immunopharmacology

Volumn 2, Issue 10, 2002, Pages 1465-1475

  Freund, Yvonne R ^a   Dousman, Linda ^a   Mohagheghpour, Nahid ^a  

^a SRI INTERNATIONAL   (United States)

Author keywords

Azidothymidine (AZT); Clarithromycin; Hematotoxicity; Immunosuppression; Mycobacterium avium complex; Zidovudine (ZDV)

Indexed keywords

ALLOANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CLARITHROMYCIN; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; FEMALE; HEMATOLOGY; HEMATOPOIESIS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE; LYMPHOPOIESIS; MACROCYTIC ANEMIA; MALE; MORTALITY; MOUSE; MYCOBACTERIUM AVIUM; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; AIDS RELATED COMPLEX; ANIMAL; ATYPICAL MYCOBACTERIOSIS; BAGG ALBINO MOUSE; CELL LINE; DOSE RESPONSE; HUMAN; LYMPHOCYTE ACTIVATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; CELL LINE; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIESIS; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOPOIESIS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; ZIDOVUDINE;

EID: 0036711070     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00092-9     Document Type: Article

References (49)

1. Dautzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res. Microbiol. 145:1994;197-205.
2. Dube M.R., Sattler F.R., Torriani F.J., See D., Havlir D.V.et al. California collaborative treatment group A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J. Infect. Dis. 176:1997;1225-1232.
3. Hawkins C.C., Gold J.W., Whimbey E., Kiehn T.E., Brannon P.et al. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 111:1986;184-188.
4. Horsburgh C.R. Jr. Mycobacterium avium complex in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:1991;1332-1338.
5. Nightingale S.D., Byrd L.T., Southern P.M., Jockusch J.D., Cal S.X., Wynne B. Incidence of Mycobacterium avium-interacellulare complex bacteremia in human immunodeficiency virus-positive patients. J. Infect. Dis. 165:1992;1082-1085.
6. Horsburg C.R. Jr., Havlik J.A., Ellis D.A., Kennedy E., Fann S.A., Dubois R.E. Survival of patients with acquired immunodeficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am. Rev. Respir. Dis. 144:1991;557-559.
7. Jacobson M.A., Hopewell P.C., Yajko D.M., Hadley W.K., Lazarus E.et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J. Infect. Dis. 164:1991;994-998.
8. Chaisson R.E., Moore R.D., Richman D.D., Keruly J., Creagh T. The zidovudine epidemiology study group Incidence and natural history of Mycobacterium avium - complex infections in patients with advanced HIV disease treated with zidovudine. Am. Rev. Respir. Dis. 146:1992;285-289.
9. Aberg J.A., Yajko D.M., Jacobson M.A. Eradication of AIDS-related disseminated Mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J. Infect. Dis. 178:1998;1446-1449.
10. Agins B.D., Berman D.S., Spicehandler D., el-Sadr W., Simberkoff M.S., Rahal J.J. Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS. J. Infect. Dis. 159:1989;784-787.
11. Masur H., Tuazon C., Gill V., Grimes G., Baird B.et al. Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. J. Infect. Dis. 155:1987;127-129.
12. Fernandes P.B., Hardy D.J., McDaniel D., Hanson C.W., Swanson R.N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob. Agents Chemother. 33:1989;1531-1536.
13. Heifets L.B., Lindholm-Levy P.J., Comstock R.D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am. Rev. Respir. Dis. 145:1992;856-858.
14. Bermudez L.E. Potential role of cytokines in disseminated mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 13(Suppl. 2):1994;29-33.
15. Klemens S.P., DeStefano M.S., Cynamon M.H. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 36:1992;2413-2417.
16. Burman W.J., Stone L.S., Rietmeijer C.A., Maslow J., Cohn D.L., Reves R.R. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. AIDS. 12:1998;1309-1315.
17. Chaisson R.E., Benson C.A., Dube M.P., Heifets L.B., Korvick J.A.et al. AIDS clinical trials group protocol 157 study team Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann. Intern. Med. 121:1994;905-911.
18. Dautzenberg B., Truffot C., Legris S., Meyohas M.C., Berlie H.C.et al. Activity of clarithromycin against Mycobacterium avium infections in patients with the acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 144:1991;564-569.
19. Pierce M., Crampton S., Henry D., Heifets L., LaMarca A.et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med. 335:1996;384-391.
20. Anderson R., Joone G., Van Rensburg C.E.J. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J. Antimicrob. Chemother. 22:1988;923-933.
21. Ishiguro M., Koga H., Kohno S., Hayashi T., Yamaguchi K., Hirota M. Penetration of macrolides into human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 27(Suppl. A):1989;1-9.
22. Peters D.H., Clissold S.P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetics properties and therapeutic potential. Drugs. 44:1992;117-164.
23. Rodvold K.A. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:1999;385-398.
24. Neu H.C. The development of macrolides: clarithromycin in perspective. J. Antimicrob. Chemother. 27(Suppl. A):1991;1-9.
25. Heifets L., Mor N., Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob. Agents. Chemother. 37:1993;2364-2370.
26. Goldberger M., Masur H. Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems. Ann. Intern. Med. 121:1994;974-976.
27. National Institute of Allergy and Infectious Diseases (NIAID) A Note to Physicians: Important Therapeutic Information on the Dosing of Clarithromycin for the Treatment of Disseminated Mycobacterium avium complex (DMAC) Infection in HIV-infected Patients. 1996;National Institutes of Health, Bethesda, MD.
28. Matsuoka N., Eguchi K., Kawakami A., Tsuboi M., Kawabe Y.et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin. Exp. Immunol. 104:1996;501-508.
29. Morikawa K., Oseko F., Morikawa S., Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother. 38:1994;2643-2647.
30. Morikawa K., Watabe H., Araake M., Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrobiol. Agents Chemother. 40:1996;1366-1370.
31. Takeshita K., Yamagishi I., Harda M., Otomo S., Nakagawa T., Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp. Clin. Res. 15:1989;527-533.
32. Guleria I., Mkherjee R., Kaufmann S.H.E. In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium vaccine-induced protection against M. tuberculosis. Med. Microbiol. Immunol. 182:1993;129-135.
33. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A.et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1996;1941-1949.
34. Orme I.M., Furney S.K., Roberts A.D. Dissemination of enteric Mycobacterium avium infections in mice rendered immunodeficient by thymectomy and CD4 depletion or by prior infection with murine AIDS retroviruses. Infect. Immun. 60:1992;4747-4753.
35. Small P.M., Hopewell P.C., Singh S.P., Paz A., Parsonnet J.et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N. Engl. J. Med. 330:1994;1703-1709.
36. Freund Y.R., Riccio E.S., Phillips S.J., Dousman L., MacGregor J.T. Pyrimethamine impairs host resistance to infection with Listeria monocytogenes in BALB/c mice. Toxicol. Sci. 42:1998;91-98.
37. Chappel W.R., Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Testa B. Advances in drug research. 1991;2-112 Academic Press, New York.
38. Forsgren A., Back G., Beckman H., Bellahsene A. Antibiotic-host defense interactions in vitro and in vivo. Scand. J. Infect. Dis. 24:1980;195-203. (Suppl.).
39. Luster M.I., Germolec D.R., White K.L.J., Fuchs B.A., Fort M.M.et al. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment. Toxicol. Appl. Pharmacol. 101:1989;328-339.
40. Cronkite E.P., Bullis J. In vivo toxicity of 3′-azido-3′-deoxythymidine (AZT) on CBA/Ca mice. Int. J. Cell Cloning. 8:1990;332-345.
41. Pizzo P.A., Eddy J., Falloon J., Balis F.M., Murphy R.F.et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N. Engl. J. Med. 319:1988;889-896.
42. Richman D.D., Fischl M.A., Grieco M.H., Gottlieb M.S., Volberding P.A.et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med. 317:1987;192-197.
43. Gallicchio V.S., Doukas M.A., Hulette B.C., Hughes N.K., Gass C. Protection of 3′-azido-3′-deoxythymidine induced toxicity to murine hematopoietic progenitors (CFU-GM, BFU-E, and CFU-MEG) with interleukin. Proc. Soc. Exp. Biol. Med. 199:1989;201-204.
44. Polis M.A., Piscitelli S.C., Vogel S., Witebsky F.G., Conville P.S.et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:1997;1709-1714.
45. Rana K.Z., Darnoeski J.W., Strayer A.H., Dudley M.N. Clarithromycin does not affect phosphorylation of zidovudine in vitro. Antimicrob. Agents Chemother. 40:1996;1945-1947.
46. Good S.S., Durack D.T., De Miranda P. Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for the treatment of AIDS. Fed. Proc. 45:1986;444.
47. McKallip R.J., Nagarkatti M., Nagarkatti P.S. Immunotoxicity of AZT: inhibitory effect on thymocyte differentiation and peripheral T cell responsiveness to gp 120 of human immunodeficiency virus. Toxicol. Appl. Pharmacol. 131:1995;53-62.
48. Luster M.I., Munson A.E., Thomas P.T., Holsapple M.P., Fenters J.D.et al. Development of a testing battery to assess chemical-induced immunotoxicity: National Toxicology Program's guidelines for immunotoxicity evaluation in mice. Fundam. Appl. Toxicol. 10:1988;2-19.
49. Pacifici R., Bacosi A., Caronna A., Carlo S.D., Pichini S., Zuccaro P. Immunological consequences of zidovudine treatment in control and morphine or methadone treated mice. Immunopharmacol. Immunotoxicol. 14:1992;355-381.